Navigation Links
Accuray Hires General Manager for the Asia Pacific Region
Date:10/28/2010

SUNNYVALE, Calif., Oct. 28 /PRNewswire-FirstCall/ -- Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, announced today that Bob Wong has returned to Accuray as General Manager of the APAC (Asia Pacific, including Australia but excluding India and Japan) region effective October 14, 2010.

Wong previously served as Managing Director of Accuray's APAC region from 2005 to 2008. During that time, Wong helped build Accuray's operation in the APAC region and successfully lead sales initiatives. After leaving Accuray, Wong remained active in the medical field and held various business leadership positions both at IMRIS Inc. and Haemonetics.

"We are happy to welcome Bob Wong back to Accuray. Wong's more than 26 years of work experience with 20 years in the medical capital equipment business along with his network of industry contacts in the APAC region and successful sales track record, will make him an asset to Accuray's APAC operations," said Euan S. Thomson, Ph.D., president and chief executive officer of Accuray Incorporated. "The APAC region already accounts for more than 10 percent of Accuray's installation base. Under Wong's leadership, Accuray is well-positioned to continue growing its global footprint."

Wong will report to Accuray's president and chief executive officer, Euan Thomson, and will be fully responsible for leading sales, service and marketing for the APAC region.

Presently there are 24 CyberKnife Systems installed throughout the APAC region.

About the CyberKnife® Robotic Radiosurgery System

The CyberKnife Robotic Radiosurgery System is the world's only robotic radiosurgery system designed to treat tumors anywhere in the body non-invasively. Using continual image guidance technology and computer controlled robotic mobility, the CyberKnife System automatically tracks, detects and corrects for tumor and patient movement in real-time throughout the treatment. This enables the CyberKnife System to deliver high-dose radiation with pinpoint precision, which minimizes damage to surrounding healthy tissue and eliminates the need for invasive head or body stabilization frames.

About Accuray

Accuray Incorporated (Nasdaq: ARAY), based in Sunnyvale, Calif., is a global leader in the field of radiosurgery dedicated to providing an improved quality of life and a non-surgical treatment option for those diagnosed with cancer. Accuray develops and markets the CyberKnife Robotic Radiosurgery System, which extends the benefits of radiosurgery to include extracranial tumors, including those in the spine, lung, prostate, liver and pancreas. To date, the CyberKnife System has been used to deliver more than 100,000 treatments worldwide and more than 206 systems have been installed in leading hospitals in the Americas, Europe and Asia. For more information, please visit www.accuray.com.

Safe Harbor Statement

The foregoing may contain certain forward-looking statements that involve risks and uncertainties, including uncertainties associated with the medical device industry. Except for the historical information contained herein, the matters set forth in this press release, including statements relating to management experience and clinical adoption are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements speak only as of the date the statements are made and are based on information available at the time those statements are made and/or management's good faith belief as of that time with respect to future events. You should not put undue reliance on any forward-looking statements. Important factors that could cause actual performance and results to differ materially from the forward-looking statements we make include: market acceptance of products; competing products, the combination of our products with complementary technology; and other risks detailed from time to time under the heading "Risk Factors" in our report on Form 10-K for the 2010 fiscal year which has been filed with the Securities and Exchange Commission on August 31, 2010. The Company's actual results of operations may differ significantly from those contemplated by such forward-looking statements as a result of these and other factors. We assume no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws.


'/>"/>
SOURCE Accuray Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Accuray Incorporated to Speak at Oppenheimers 21st Annual Healthcare Conference
2. Accuray Incorporated to Report Financial Results for First Quarter of Fiscal 2011
3. Accuray Ranked Number 113 Fastest Growing Company in North America on Deloittes 2010 Technology Fast 500™
4. Accuray Incorporated to Host Analyst Meeting at ASTRO 2010
5. 100,000th Patient Treated With Accurays CyberKnife® Robotic Radiosurgery System
6. Accuray Awarded $1 Million Grant by U.S. Government
7. Accuray Incorporated to Speak at JMP Securities Healthcare Conference
8. Accuray Incorporateds CEO to Speak at UBS Global Life Sciences Conference
9. Accuray Announces Results for Fourth Quarter and Fiscal Year 2010
10. Accurays CyberKnife® G4 System Receives Shonin Approval
11. Accuray Incorporateds CEO to Speak at BMO Capital Markets Tenth Annual Focus on Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... , Germany and ... QIAGEN N.V. (NASDAQ: QGEN ; Frankfurt Prime ... a licensing and co-development agreement with Therawis Diagnostics GmbH to ... will be to develop and market PITX2 as a marker ... other high-risk breast cancer patients. "We are pleased ...
(Date:5/25/2016)... 25, 2016 As illustrated by ... this month, the numbers and momentum of cannabis in ... into the billions, more research and development push the ... State of Legal Marijuana Markets Report  from from ArcView ... much of the increase in sector is attributed to ...
(Date:5/25/2016)... , May 25, 2016 ... the precision of circulating tumour DNA (ctDNA) analysis ... the appointment of Professor Clive Morris ... leadership across the clinical development programme, scientific collaborations, ... help deliver significant improvements in clinical outcomes for ...
Breaking Medicine Technology:
(Date:5/26/2016)... ... May 26, 2016 , ... Despite last week’s media reports hinting at ... company to wait until March 2017 for an interest rate increase, according to Rajeev ... of Business. , “The Federal Open Market Committee (FOMC) dot charts are of interest ...
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... ... with discovery of thousands of defective respirators, according to court documents and SEC ... case of William and Becky Tyler v. American Optical Corporation, Case No. BC588866, ...
(Date:5/26/2016)... ... May 26, 2016 , ... Connor Sports, ... as a partner for the Tamika Catchings Legacy Tour that will commemorate ... leader in hardwood basketball surfaces in all forms and levels of the game, Connor ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... a significant negative impact on long-term patient survival, reports a team of UPMC ... online this week in the Journal of Thoracic and Cardiovascular Surgery, provide critical ...
(Date:5/26/2016)... ... May 26, 2016 , ... Catalent Pharma Solutions, the ... consumer health and global clinical supply services, today announced two key appointments and ... continued investment and strategic growth plans in the Asia Pacific region. , Howard ...
Breaking Medicine News(10 mins):